Israel Englander Millennium Management
Israel “Izzy” Englander is the founder of Millennium Management, one of the world’s largest multi-strategy hedge fund platforms. Millennium allocates capital across hundreds of independent teams rather than a single house view, with rigorous risk controls at the platform level. Englander’s model has been highly influential in the rise of pod-shop multi-manager structures across the industry.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$643M |
| 2 |
AT&T
T
|
+$311M |
| 3 |
State Street Technology Select Sector SPDR ETF
XLK
|
+$306M |
| 4 |
Microsoft
MSFT
|
+$292M |
| 5 |
Ametek
AME
|
+$215M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$887M |
| 2 |
Apple
AAPL
|
+$694M |
| 3 |
PRAH
PRA Health Sciences, Inc.
PRAH
|
+$616M |
| 4 |
Amazon
AMZN
|
+$596M |
| 5 |
Linde
LIN
|
+$531M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 58.05% |
| 2 | Technology | 7.69% |
| 3 | Financials | 6.83% |
| 4 | Healthcare | 6.42% |
| 5 | Industrials | 4.98% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
4251
PUT
Tapestry
TPR
$25B
| $1.42M | ﹤0.01% |
38,300
-43,800
| -53% | -$1.8M |
|
4252
Vanguard Morningstar Value ETF
VTV
$192B
| $1.42M | ﹤0.01% |
+10,471
| New | +$1.46M |
|
|
PUCK
4253
DELISTED
Goal Acquisitions Corp. Common Stock
PUCK
| $1.42M | ﹤0.01% |
145,818
+108,876
| +295% | +$1.05M |
|
|
CONE
4254
CALL
DELISTED
CyrusOne Inc Common Stock
CONE
| $1.42M | ﹤0.01% |
+18,300
| New | +$1.38M |
|
4255
Treace Medical Concepts
TMCI
$302M
| $1.41M | ﹤0.01% |
52,575
+42,788
| +437% | +$1.18M |
|
4256
X4 Pharmaceuticals
XFOR
$401M
| $1.41M | ﹤0.01% |
8,912
-3,955
| -31% | -$651K |
|
|
SYRS
4257
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
| $1.41M | ﹤0.01% |
31,638
-24,133
| -43% | -$1.18M |
|
4258
Hanover Insurance
THG
$7.93B
| $1.41M | ﹤0.01% |
10,903
-61,262
| -85% | -$8.34M |
|
4259
Aquestive Therapeutics
AQST
$630M
| $1.41M | ﹤0.01% |
323,774
-114,080
| -26% | -$447K |
|
4260
CALL
QuidelOrtho
QDEL
$1.01B
| $1.41M | ﹤0.01% |
+10,000
| New | +$1.34M |
|
4261
CALL
Fortive
FTV
$18B
| $1.41M | ﹤0.01% |
26,540
+13,270
| +100% | +$726K |
|
4262
Insulet
PODD
$10.1B
| $1.41M | ﹤0.01% |
4,957
-113,941
| -96% | -$32.5M |
|
4263
PUT
Cardinal Health
CAH
$54.6B
| $1.41M | ﹤0.01% |
+28,400
| New | +$1.54M |
|
|
MILE
4264
DELISTED
Metromile, Inc. Common Stock
MILE
| $1.4M | ﹤0.01% |
395,539
+145,539
| +58% | +$821K |
|
4265
NextDecade
NEXT
$1.96B
| $1.4M | ﹤0.01% |
504,580
-404,771
| -45% | -$1.28M |
|
4266
Forestar Group
FOR
$1.46B
| $1.4M | ﹤0.01% |
75,232
+11,765
| +19% | +$238K |
|
|
RTLR
4267
DELISTED
Rattler Midstream LP Common Units
RTLR
| $1.4M | ﹤0.01% |
119,448
-7,810
| -6% | -$84.6K |
|
4268
Alliant Energy
LNT
$17.6B
| $1.4M | ﹤0.01% |
25,022
-13,250
| -35% | -$783K |
|
4269
Vanguard Energy ETF
VDE
$10.7B
| $1.4M | ﹤0.01% |
18,957
+15,141
| +397% | +$1.06M |
|
4270
Genasys
GNSS
$66M
| $1.4M | ﹤0.01% |
270,252
-375,560
| -58% | -$2.02M |
|
|
SLAMU
4271
DELISTED
Slam Corp. Unit
SLAMU
| $1.4M | ﹤0.01% |
141,000
-827,311
| -85% | -$8.25M |
|
4272
Stoke Therapeutics
STOK
$2.04B
| $1.4M | ﹤0.01% |
+54,825
| New | +$1.53M |
|
4273
CALL
Willis Towers Watson
WTW
$31.9B
| $1.4M | ﹤0.01% |
6,000
-29,600
| -83% | -$6.59M |
|
|
PARA
4274
Banzai International
PARA
$3.87M
| $1.39M | ﹤0.01% |
14
+8
| +133% | +$776K |
|
|
ADN
4275
DELISTED
Advent Technologies
ADN
| $1.39M | ﹤0.01% |
+5,334
| New | +$1.3M |
|
Similar funds
Israel Englander's Q3 2021 Portfolio in Review
As of Q3 2021, Israel Englander held 7,698 positions worth $167B, up 2.3% from $163B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
Israel Englander's Q3 2021 filing shows 1,245 new, 2,719 increased, 2,446 reduced and 981 closed positions. Its largest new stake was Sight Sciences: 1,577,092 shares worth $35.8M. The largest sale was Alexion Pharmaceuticals, an estimated $887M.
By sector, the portfolio is most concentrated in Miscellaneous at 58% of assets, up from 55% a quarter earlier, followed by Technology and Financials.
- Israel Englander's largest Q3 2021 buy was Sight Sciences: 1,577,092 shares worth $35.8M.
- Israel Englander added most to State Street SPDR S&P 500 ETF Trust in Q3 2021, an estimated $643M increase.
- Israel Englander's biggest Q3 2021 reduction was Apple, cutting an estimated $694M.
- Israel Englander fully exited Alexion Pharmaceuticals in Q3 2021, selling an estimated $887M.
- Israel Englander's ten largest holdings make up 18% of its $167B portfolio in Q3 2021.
- Israel Englander opened 1,245 new positions and closed 981 in Q3 2021.
- Israel Englander's portfolio value rose 2.3% quarter-over-quarter to $167B.
Based on Millennium Management's 13F filing for Q3 2021, filed 15 Nov 2021.